Company Focus
Daiichi Sankyo
Latest Daiichi Sankyo News
Biotechnology
The US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan or Dato-DXd) to treat adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. 24 June 2025
Related News
Insights
Company Spotlight
A privately-held biotech company developing multiple-dose gene therapies to treat patients with genetic and idiopathic diseases, focusing first on hemophilia B.
Latest News & Features of interest to Daiichi Sankyo
Biotechnology
China-based biotech Biocytogen has signed a global licensing agreement with oncology-focused BeOne Medicines, handing over rights to multiple fully human antibodies discovered through its proprietary RenMice platform. 10 July 2025
Biotechnology
The European Commission has approved Tevimbra (tislelizumab), alongside gemcitabine and cisplatin, for the first-line treatment of adults with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. 10 July 2025
Biotechnology
US pharma major AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases. 10 July 2025
Biotechnology
BeOne Medicines - the Sino-American oncology specialist formerly known as BeiGene - has announced that the National Institute for Health and Care Excellence (NICE) has recommended Brukinsa (zanubrutinib) to treat relapsed or refractory mantle cell lymphoma (MCL) after one line of treatment. 10 July 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted the supplemental new drug application (sNDA) for Inqovi (decitabine and cedazuridine) plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy. 10 July 2025
Pharmaceutical
Secarna Pharmaceuticals has formed a strategic collaboration with Vect-Horus aimed at advancing RNA-targeted therapies capable of crossing the blood-brain barrier, a key hurdle in treating central nervous system disorders. 10 July 2025
Biotechnology
Japanese authorities are putting Eisai under pressure to reconsider the price of its Alzheimer’s disease therapy Leqembi (lecanemab), after a government-backed review found that the drug significantly exceeds accepted cost-effectiveness thresholds in the country. 10 July 2025
Pharmaceutical
US pharma major Eli Lilly’s C is emerging as a promising oral glucagon-like peptide (GLP)-1 therapy, with upcoming clinical milestones in obesity and diabetes set to shape its market trajectory. 10 July 2025
Pharmaceutical
Singapore-based market expansion services provider DKSH Business Unit Healthcare announced a partnership with Germany’s Bayer. 10 July 2025
Biotechnology
Radiant Biotherapeutics, a Canadian biotech advancing multi-specific, multi-affinity antibody (Multabody) therapeutics in cancer and autoimmune diseases, has announced the appointment of Deborah Geraghty as president and chief executive. 9 July 2025
Latest In Brief for Daiichi Sankyo
Biotechnology
US biotech Nanoscope Therapeutics has begun a rolling submission to the American medicines regulator for MCO-010, the first gene-agnostic therapy seeking approval for retinitis pigmentosa (RP). 15 July 2025
Latest Relevant Ones To Watch News
US pharma giant Merck & Co today revealed it has made a bid to acquire UK-based lung therapy company Verona Pharma, sending the latter’s shares up 20.4% to $104.61 in pre-market activity. 13 July 2025
17 June 2025
16 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze